Press Releases
Press Releases
CRF Health Scoops 2018 TrialConsent® Hat Trick as CARE Award Finalist
CRF Health, the leading provider of patient-centered eSource for the life sciences industry, announced that its TrialConsent® electronic informed consent solution has been shortlisted for the ‘Best Patient-Focused Technological Development’ category in the 2018 Clinical & Research Excellence (CARE)...
Press Releases
Biotech uses New Technology to fight Cardiovascular Diseases
Despite significant technological advances in technology, cardiovascular diseases (CVDs) remain the number one cause of death globally. CVDs are a group of disorders of both the heart and blood vessels that can lead to heart attacks and strokes. ...
Press Releases
Alma Lasers Inc., receives new FDA clearance soprano ICE platform, Indicating a new era in Aesthetic technology Advancement
Alma Lasers, a subsidiary of Sisram Medical Ltd , the leading global innovator of laser light-based, radio frequency and ultrasound solutions for the aesthetic and surgical markets and the #1 rated leading provider of energy-based surgical and medical aesthetic...
Press Releases
Study claims the Importance of familiarizing the risks and benefits of phase 1 trials in pediatric cancer
On average, 1 in 10 children who enroll in pediatric phase I cancer trials are improved after the trial, and 1 in 50 die from drug-related complications, according to a new systematic review and meta-analysis published this week in...
Press Releases
FDA Approval for Allegra’s filing for supplemental new drug application LILETTA®
Allergan plc, a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the U.S. FDA has accepted for filing Medicines360's supplemental New Drug...
Press Releases
AbbVie and Voyager Therapeutics collaborates for Neurodegenerative Diseases
AbbVie , a global biopharmaceutical company, and Voyager Therapeutics, Inc. , a clinical-stage gene therapy company announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for...
Press Releases
Astrazeneca’s Imfinzi for unresectable Stage III non-small cell lung cancer gets FDA approval
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US FDA has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
